Levosimendan Reig Jofre (Levosimendan)

Levosimendan works by binding to cardiac troponin C, which makes the heart muscle more responsive to existing calcium, thereby strengthening contractions without raising intracellular calcium. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, leading to vasodilation and reduced cardiac workload.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s clinical status, weight, and renal function. Typically, an initial loading dose may be followed by a continuous infusion, but exact regimens are individualized and should follow local prescribing guidelines.

Safety data for levosimendan during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under specialist supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with traditional inotropes such as dobutamine or milrinone, levosimendan increases contractility without markedly raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilatory effects, potentially improving both preload and afterload, whereas other agents primarily act as pure stimulants of myocardial contractility.

Levosimendan should be stored below 25 °C, protected from light, and kept in its original packaging to maintain stability. Once reconstituted, the solution should be used within the time frame recommended by the manufacturer and discarded if any discoloration or particulate matter is observed.

Levosimendan is given intravenously, usually as an initial loading infusion followed by a continuous maintenance infusion. Administration is performed in a monitored clinical setting, such as an intensive care unit, where blood pressure, heart rate, and cardiac output can be continuously observed.

The most serious risks include severe hypotension, which can lead to organ hypoperfusion, and potentially life‑threatening ventricular arrhythmias. Myocardial ischaemia and significant liver enzyme elevations have also been reported, so patients should be closely monitored for these events during therapy.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension unresponsive to treatment, and individuals with significant obstructive cardiac outflow lesions. Caution is also advised for patients with severe hepatic impairment or uncontrolled arrhythmias.